Ahrens Brenton Karl 4
4 · Iterum Therapeutics plc · Filed Dec 28, 2022
Insider Transaction Report
Form 4
Ahrens Brenton Karl
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-12-23$0.81/sh+29,125$23,591→ 29,125 totalExercise: $0.81Exp: 2032-12-22→ Ordinary Shares (29,125 underlying)
Footnotes (1)
- [F1]Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the shares subject to this option shall vest in full on October 1, 2023.